1 day Ago By ABMN Staff
InspireMD ( NYSE:NSPR – Get Free Report ) ‘s stock had its “overweight” rating reiterated by equities researchers at Piper Sandler in a report issued on Tuesday, Benzinga reports. They presently have a $4.50 price target on the stock.
Piper Sandler’s target price suggests a potential upside of 71.10% from the stock’s previous close. Separately, StockNews.
com initiated coverage on InspireMD in a research report on Sunday. They issued a “sell” rating on the stock. Read Our Latest Analysis on NSPR InspireMD Stock Up 3.
1 % InspireMD ( NYSE:NSPR – Get Free Report ) last posted its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.
19) by ($0.03). InspireMD had a negative return on equity of 62.
02% and a negative net margin of 388.67%. The firm had revenue of $1.
74 million for the quarter, compared to the consensus estimate of $1.74 million. During the same period last year, the company posted ($0.
24) EPS. Analysts expect that InspireMD will post -0.82 earnings per share for the current fiscal year.
Institutional Inflows and Outflows An institutional investor recently bought a new position in InspireMD stock. Mesirow Financial Investment Management Inc. purchased a new position in InspireMD, Inc.
( NYSE:NSPR – Free Report ) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 30,000 shares of the company’s stock, valued at approximately $71,000. Mesirow Financial Investment Management Inc.
owned approximately 0.13% of InspireMD at the end of the most recent reporting period. Hedge funds and other institutional investors own 44.
78% of the company’s stock. About InspireMD ( Get Free Report ) InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
See Also Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter ..
